주주 소통 손 내민 강스템바이오텍, 오스카·오가노이드 성과 공유

Kangstem Biotech is pivoting toward proactive shareholder engagement to rebuild market trust following recent governance criticisms. This strategic transparency is timed with critical milestones for its osteoarthritis pipeline, OSCA, and the commercial scaling of its Organoid business, highlighting the increasing importance of investor relations in the biotech sector.